Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontier Study: Fosnetupitant as Antiemetic with nal-IRI + 5-FU/l-LV in Unresectable Pancreatic Cancer
jRCT1051240032Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of fosnetupitant in pancreatic cancer (PC) and pancreatic adenosquamous carcinoma (PASC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall (0–120 h) complete response rate. Started Apr 2024; status: recruiting.
02
Drugs
fosnetupitant
03
Conditions
pancreatic cancer (PC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCT1051240032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051240032.